The law firm of Kirby McInerney LLP is investigating potential claims against Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX). The investigation concerns whether Eagle and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

On November 9, 2023, Eagle issued a press release stating that the Company “will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today . . . . The Company requires more time to review potential adjustments relating to the reporting of sales of PEMFEXY® prior to filing its Form 10-Q. In addition, the Company expects to revise its previously disclosed 2023 full year guidance downward.” On this news, the price of Eagle shares declined by $4.16 per share, or approximately 30.36%, from $13.70 per share to close at $9.54 on November 9, 2023.

On November 29, 2023, Eagle issued a press release stating, “[e]ffective immediately Scott Tarriff, Founder, President and Chief Executive Officer of the Company, has announced his resignation and retirement from his positions with the Company as President, Chief Executive Officer and Director on the Company’s Board of Directors.” On this news, the price of Eagle shares declined by $2.55 per share, or approximately 30.98%, from $8.23 per share to close at $5.68 on November 29, 2023.

If you purchased or otherwise acquired Eagle securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: https://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231130830532/en/